Dapansutrile
Dapansutrile is a small molecule pharmaceutical. It is currently being investigated in clinical studies. It is known to target NACHT, LRR and PYD domains-containing protein 3.
Download report
Favorite
Commercial
Therapeutic Areas
No data
Trade Name
FDA
EMA
No data
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
No data
Labels
FDA
EMA
No data
Indications
FDA
EMA
No data
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
ATC Codes
No data
HCPCS
No data
Clinical
Clinical Trials
10 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
No data
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Arthritis | D001168 | EFO_0005856 | M05-M14 | — | 1 | 1 | — | — | 1 |
| Arthralgia | D018771 | HP_0002829 | M25.5 | — | 1 | 1 | — | — | 1 |
| Gouty arthritis | D015210 | — | 1 | 1 | — | — | 1 | ||
| Gout | D006073 | EFO_0004274 | M10 | — | 1 | 1 | — | — | 1 |
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Schnitzler syndrome | D019873 | EFO_1001165 | — | 1 | — | — | — | 1 | |
| Covid-19 | D000086382 | U07.1 | — | 1 | — | — | — | 1 | |
| Cytokine release syndrome | D000080424 | D89.83 | — | 1 | — | — | — | 1 | |
| Pain | D010146 | EFO_0003843 | R52 | — | 1 | — | — | — | 1 |
| Osteoarthritis | D010003 | EFO_0002506 | M15-M19 | — | 1 | — | — | — | 1 |
| Knee osteoarthritis | D020370 | EFO_0004616 | M17 | — | 1 | — | — | — | 1 |
| Melanoma | D008545 | 1 | 1 | — | — | — | 1 |
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Healthy volunteers/patients | — | 2 | — | — | — | — | 2 | ||
| Systolic heart failure | D054143 | EFO_1001207 | I50.20 | 1 | — | — | — | — | 1 |
Indications Without Phase
No data
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | DAPANSUTRILE |
| INN | dapansutrile |
| Description | Dapansutrile (OLT1177) is an inhibitor of the NLRP3 (nucleotide-binding domain leucine-rich repeat and pyrin domain containing receptor 3) inflammasome.
|
| Classification | Small molecule |
| Drug class | — |
| Image (chem structure or protein) | |
| Structure (InChI/SMILES or Protein Sequence) | CS(=O)(=O)CCC#N |
Identifiers
| PDB | — |
| CAS-ID | 54863-37-5 |
| RxCUI | — |
| ChEMBL ID | CHEMBL3989943 |
| ChEBI ID | — |
| PubChem CID | 12714644 |
| DrugBank | DB16130 |
| UNII ID | 2Z03364G96 (ChemIDplus, GSRS) |
Target
Agency Approved
No data
Alternate
NLRP3
NLRP3
Organism
Homo sapiens
Gene name
NLRP3
Gene synonyms
C1orf7, CIAS1, NALP3, PYPAF1
NCBI Gene ID
Protein name
NACHT, LRR and PYD domains-containing protein 3
Protein synonyms
Angiotensin/vasopressin receptor AII/AVP-like, Caterpiller protein 1.1, CLR1.1, cold autoinflammatory syndrome 1 protein, Cold-induced autoinflammatory syndrome 1 protein, Cryopyrin, cryopyrin, NACHT, LRR and PYD domains - containing protein 3, deafness, autosomal dominant 34, NACHT domain-, leucine-rich repeat-, and PYD-containing protein 3, NACHT, LRR and PYD containing protein 3, nucleotide-binding oligomerization domain, leucine rich repeat and pyrin domain containing 3, PYRIN-containing APAF1-like protein 1
Uniprot ID
Mouse ortholog
Nlrp3 (216799)
NACHT, LRR and PYD domains-containing protein 3 (T1W2H6)
Variants
Clinical Variant
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 204 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
0 adverse events reported
View more details
Premium feature
Learn more about premium features at pharmakb.com
Learn more